Source comparison
Tesamorelin + Ipamorelin Blend Daily Dose: Research Protocol Comparison
Standard Research (Adults) 200–300 mcg Once daily (evening) 12–16 weeks Baseline protocol. Reliable IGF-1 response, minimal side effects, suitable for most metabolic research applications High-Dose Titration 300–500 mcg 8–12 weeks Reserved for subjects with bl
This comparison does not assign a generated winner or score.
- Standard Research (Adults)
- 200–300 mcg
- Once daily (evening)
- 12–16 weeks
- Baseline protocol. Reliable IGF-1 response, minimal side effects, suitable for most metabolic research applications
- High-Dose Titration
- 300–500 mcg
- 8–12 weeks
- Reserved for subjects with blunted GH response (age >50, metabolic syndrome). Monitor fasting glucose weekly
- Low-Dose Maintenance
- 100–150 mcg
- 16–24 weeks
- Used post-titration to sustain IGF-1 gains without receptor desensitisation. Extend duration, reduce dose
- Twice-Daily Split
- 200 mcg (AM + PM)
- Twice daily
- 8 weeks maximum
- Not recommended. No IGF-1 advantage, higher hyperglycaemia risk, increased receptor downregulation
- The standard protocol (200–300 mcg once daily) produces mean IGF-1 increases of 25–50 ng/mL from baseline across most adult populations. High-dose protocols escalate to 500 mcg only when 300 mcg fails to produce measurable IGF-1 response after 4 weeks. Low-dose maintenance extends research timelines without cumulative receptor fatigue.